Berezin et al., 2016 - Google Patents
Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failureBerezin et al., 2016
View PDF- Document ID
- 1369049733071702537
- Author
- Berezin A
- Kremzer A
- Cammarota G
- Zulli A
- Petrovic D
- Martell-Claros N
- Sabo J
- Kruzliak P
- Publication year
- Publication venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
External Links
Snippet
Background: The objective of this study was to assess the relationship between insulin resistance and apoptotic endothelial-derived microparticles (EMPs) in patients with chronic heart failure (CHF). Methods: The study involved 300 CHF patients (186 males) aged 48–62 …
- 206010022489 Insulin resistance 0 title abstract description 73
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—G01N2333/4701
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berezin et al. | Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure | |
| Persson et al. | Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease | |
| Willeit et al. | High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants | |
| Berezin et al. | Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction | |
| White | Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? | |
| Mussap et al. | Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges | |
| Di Napoli et al. | C-reactive protein in intracerebral hemorrhage: time course, tissue localization, and prognosis | |
| Chirinos et al. | Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism | |
| Ali et al. | Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis | |
| Fontana et al. | Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C | |
| Otaki et al. | Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study | |
| Schrijver et al. | Myeloperoxidase can differentiate between sepsis and non-infectious SIRS and predicts mortality in intensive care patients with SIRS | |
| Garg et al. | Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction | |
| Berezin et al. | Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus | |
| Berezin et al. | The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis | |
| Dalal et al. | ST2 elevation in heart failure, predictive of a high early mortality | |
| Seyedian et al. | Relationship between high-sensitivity C-reactive protein serum levels and the severity of coronary artery stenosis in patients with coronary artery disease | |
| Collinson | The role of cardiac biomarkers in cardiovascular disease risk assessment | |
| Wei et al. | The impact of admission neutrophil-to-platelet ratio on in-hospital and long-term mortality in patients with infective endocarditis | |
| Berezin et al. | The signature of circulating microparticles in heart failure patients with metabolic syndrome | |
| Rotz et al. | The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults | |
| Sumarjaya et al. | High lipoprotein (a) levels as a predictor of major adverse cardiovascular events in hospitalized-acute myocardial infarction patients | |
| Patel et al. | A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease | |
| Govindarajan et al. | Plasma myeloperoxidase and total sialic acid as prognostic indicators in acute coronary syndrome | |
| Popp | Troponin: messenger or actor? |